图书馆订阅: Guest
医药载体系统评论综述

每年出版 6 

ISSN 打印: 0743-4863

ISSN 在线: 2162-660X

The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two preceding years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) IF: 2.7 To calculate the five year Impact Factor, citations are counted in 2017 to the previous five years and divided by the source items published in the previous five years. 2017 Journal Citation Reports (Clarivate Analytics, 2018) 5-Year IF: 3.6 The Immediacy Index is the average number of times an article is cited in the year it is published. The journal Immediacy Index indicates how quickly articles in a journal are cited. Immediacy Index: 0.8 The Eigenfactor score, developed by Jevin West and Carl Bergstrom at the University of Washington, is a rating of the total importance of a scientific journal. Journals are rated according to the number of incoming citations, with citations from highly ranked journals weighted to make a larger contribution to the eigenfactor than those from poorly ranked journals. Eigenfactor: 0.00023 The Journal Citation Indicator (JCI) is a single measurement of the field-normalized citation impact of journals in the Web of Science Core Collection across disciplines. The key words here are that the metric is normalized and cross-disciplinary. JCI: 0.39 SJR: 0.42 SNIP: 0.89 CiteScore™:: 5.5 H-Index: 79

Indexed in

Optimizing Drug Delivery for Enhancing Therapeutic Efficacy of Recombinant Human Endostatin in Cancer Treatment

卷 24, 册 5, 2007, pp. 445-492
DOI: 10.1615/CritRevTherDrugCarrierSyst.v24.i5.20
Get accessGet access

摘要

Recombinant human endostatin (rhEndostatin) is uniquely able to target neovascular endothelial cells (ECs) and has the potential for antiangiogenetic and antitumor activities. In this review, we explore experimental approaches and clinical trials focusing on drug delivery of endostatin. Continued endostatin therapy can maintain tumors in a state of dormancy, and no signs of drug-induced resistance have been observed. Prolonged delivery of endostatin may be achieved by using pumps (mini-osmotic pumps) or cell encapsulation systems. The largest benefit from rhEndostatin is expected when drug delivery of rhEndostatin is begun as early as possible. Although endostatin has shown promise in controlling tumor neovasculature, a major problem in pharmacotherapy is the side effects of constant drug administration and the limited half-life of antiangiogenic proteins. Gene therapy offers the advantages of maximizing cost effectiveness and maintaining sustained levels of antiangiogenic factors, which may enhance antitumor efficacy. Therefore, we have investigated recent advances in gene delivery of endostatin for cancer treatment. In recent years, preclinical and clinical data have demonstrated the synergistic effects of rhEndostatin combined with other therapies on inhibiting growth of malignant tumors, with minimal toxicity. rhEndostatin has not been proven to prolong the survival rate of patients challenged with cancer when used as single therapy. Thus, we suggest that the combination of rhEndostatin with chemotherapy, radiotherapy, and biotherapy (i.e., fusion protein, molecular-targeted therapy on cancers, etc.) might provide an optimal strategy for cancer treatment.

对本文的引用
  1. Yiu Humphrey H. P., Niu Hong-jun, Biermans Ellen, van Tendeloo Gustaaf, Rosseinsky Matthew J., Designed Multifunctional Nanocomposites for Biomedical Applications, Advanced Functional Materials, 20, 10, 2010. Crossref

  2. Xu Wen, Ye Panpan, Li Zhaochun, Shi Junting, Wang Wei, Yao Ke, Endostar, a recently introduced recombinant human endostatin, inhibits proliferation and migration through regulating growth factors, adhesion factors and inflammatory mediators in choroid-retinal endothelial cells, Molecular Biology, 44, 4, 2010. Crossref

  3. Karamouzis Michalis V, Moschos Stergios J, The use of endostatin in the treatment of solid tumors, Expert Opinion on Biological Therapy, 9, 5, 2009. Crossref

  4. Lu Xiao, Wang Qing-Qing, Xu Fu-Jian, Tang Gu-Ping, Yang Wan-Tai, A cationic prodrug/therapeutic gene nanocomplex for the synergistic treatment of tumors, Biomaterials, 32, 21, 2011. Crossref

  5. Retsky Michael W, Hrushesky William JM, Gukas Isaac D, Hypothesis: primary antiangiogenic method proposed to treat early stage breast cancer, BMC Cancer, 9, 1, 2009. Crossref

  6. Ricard-Blum Sylvie, Vallet Sylvain D., Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells, Frontiers in Pharmacology, 7, 2016. Crossref

  7. Sapi Johanna, Drexler Daniel Andras, Kovacs Levente, Comparison of protocol based cancer therapies and discrete controller based treatments in the case of endostatin administration, 2016 IEEE International Conference on Systems, Man, and Cybernetics (SMC), 2016. Crossref

  8. Miao Chuanwang, Zhao Wei, Yuan Shuanghu, Yu Jinming, Zhao Shuqiang, Ma Li, Zhang Dexian, Hu Xudong, A novel molecular agent for glioma angiogenesis imaging, Nuclear Medicine Communications, 38, 11, 2017. Crossref

  9. Yao Difei, Shen Hong, Huang Jianjin, Yuan Ying, Dai Haibin, Influence of different drug delivery methods for Endostar combined with a gemcitabine/cisplatin regimen in locally advanced or metastatic lung squamous cell carcinoma, Medicine, 97, 32, 2018. Crossref

  10. Buchsbaum Donald J., Miller C. Ryan, Mcnally Lacey R., Kaliberov Sergey A., Cancer gene therapy, in Principles of Cancer Biotherapy, 2009. Crossref

  11. Pedchenko Vadim, Pozzi Ambra, Basement Membrane Collagens and Cancer, in Cell-Extracellular Matrix Interactions in Cancer, 2010. Crossref

  12. Ai Jing, Sun Jun-Hui, Ma Jian, Yao Ke, Effects of lentivirus-mediated endostatin on endothelial progenitor cells, Oncotarget, 8, 55, 2017. Crossref

  13. Honglian Ma, Zhouguang Hui, Fang PENG, Lujun Zhao, Dongming Li, Yujin Xu, Yong Bao, Liming Xu, Yirui Zhai, Xiao Hu, Jin Wang, Yue Kong, Lvhua Wang, Ming Chen, Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non‐small cell lung cancer: Updated follow‐up results from two phase II trials, Thoracic Cancer, 11, 4, 2020. Crossref

  14. Mo Wei-Fang, Tong Yu-Ling, Hepatic epithelioid hemangioendothelioma after thirteen years’ follow-up: A case report and review of literature, World Journal of Clinical Cases, 10, 18, 2022. Crossref

  15. Pozzi Ambra, Zent Roy, Regulation of endothelial cell functions by basement membrane‐ and arachidonic acid‐derived products, WIREs Systems Biology and Medicine, 1, 2, 2009. Crossref

  16. Maquart François-Xavier, Les matrikines anti-tumorales : intérêt potentiel en cancérologie, Bulletin de l'Académie Nationale de Médecine, 194, 3, 2010. Crossref

  17. Ding Rui-Lin, Xie Fang, Hu Yue, Fu Shao-Zhi, Wu Jing-Bo, Fan Juan, He Wen-Feng, He Yu, Yang Ling-Lin, Lin Sheng, Wen Qing-Lian, Preparation of endostatin-loaded chitosan nanoparticles and evaluation of the antitumor effect of such nanoparticles on the Lewis lung cancer model, Drug Delivery, 24, 1, 2017. Crossref

  18. Maimaitiming Nuersimanguli, Ma Xiaoli, Wei Yu, Cao Leiyu, Gao Yan, Zhang Li, Efficacy and safety of endostar combined with chemoradiotherapy versus chemoradiotherapy alone in locally advanced cervical cancer: A PRISMA-compliant systematic review and meta-analysis, Medicine, 101, 36, 2022. Crossref

Begell Digital Portal Begell 数字图书馆 电子图书 期刊 参考文献及会议录 研究收集 订购及政策 Begell House 联系我们 Language English 中文 Русский Português German French Spain